Table 3.
Outcome | Ferritin (ng/ml) | N (%) | Hazard Ratios (95% CIs) | ||||
---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||
All-cause mortality | <50 | 777 (15) | 1.17 (0.94 to 1.45) | 1.21 (0.96 to 1.52) | 1.14 (0.91 to 1.43) | 0.97 (0.75 to 1.26) | 0.99 (0.76 to 1.28) |
50–99 | 1201 (23) | 1.00 (0.80 to 1.24) | 1.02 (0.81 to 1.28) | 1.01 (0.80 to 1.28) | 0.96 (0.75 to 1.22) | 0.97 (0.76 to 1.24) | |
100–299 | 2236 (43) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | |
≥300 | 931 (18) | 1.37 (1.10 to 1.70) | 1.29 (1.03 to 1.61) | 1.22 (0.98 to 1.53) | 1.26 (1.00 to 1.59) | 1.21 (0.96 to 1.53) | |
MACE | <50 | 431 (14) | 1.19 (0.83 to 1.68) | 1.18 (0.82 to 1.70) | 1.10 (0.78 to 1.56) | 0.92 (0.63 to 1.34) | 0.94 (0.65 to 1.36) |
50–99 | 707 (23) | 1.01 (0.76 to 1.33) | 1.03 (0.77 to 1.39) | 0.97 (0.72 to 1.30) | 0.91 (0.67 to 1.26) | 0.94 (0.70 to 1.27) | |
100–299 | 1346 (45) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | |
≥300 | 532 (18) | 1.13 (0.85 to 1.49) | 1.12 (0.85 to 1.48) | 1.01 (0.75 to 1.36) | 1.11 (0.84 to 1.47) | 1.06 (0.80 to 1.42) |
For all-cause death, the sample includes patients from Brazil, France, Germany, and the United States. For MACE, the sample includes patients from Brazil, France, and the United States. Progressive adjustments: Model 1: Unadjusted. Model 2: Country, age, sex, Black race, body mass index (BMI), eGFR and albuminuria. Model 3: + ESA use and 11 summary comorbidities. Model 4: + serum albumin, white blood cell count, and TSAT. Model 5: + Hgb.